Home > Products > Inj. K MM
Share Print This Page

Inj. K MM (Phytomenadione)
Therapeutic Group: Vitamins and Minerals
Inj. K MM

Inj. K MM paediatric: Each ampoule contains 2 mg of Phytomenadione in 0.2 ml of clear bile acid/lecithin mixed-micelle (MM) solution.

Vitamin K1 (Phytomenadione) is a procoagulant factor. As a component of a hepatic carboxylase system, Vitamin K1 is involved in the post-translational carboxylation of clotting factors II (Prothrombin), VII, IX and X and the clotting inhibitors protein C and protein S. Coumarins inhibit the reduction of Vitamin K1 (quinone form) to Vitamin K1 (hydroquinone) and also prevent the Vitamin K1 epoxide arising after carboxylation from being reduced to the quinone form.

Vitamin K1 is an antagonist of coumarin-type anticoagulants, e.g. Phenprocoumon. It does not, however, neutralise the activity of Heparin; Protamine is the antagonist of Heparin.

Vitamin K1 is ineffective in hereditary hypoprothrombinemia or hypoprothrombinemia induced by severe hepatic failure.

Lack of Vitamin K1 leads to an increased tendency to haemorrhagic disease in the newborn. Vitamin K1 administration, which promotes synthesis of the above-mentioned coagulation factors by the liver, can reverse an abnormal coagulation status and bleeding due to vitamin K1 deficiency.
Haemorrhage or risk of haemorrhage as a result of severe \'hypoprothrombinemia\' (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with Phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).

Prophylaxis and treatment of haemorrhagic disease in the newborn.
Dosage & Administration
Neonates with special risk factors (e.g. prematurity, birth asphyxia, obstructive jaundice, inability to swallow, maternal use of anticoagulants or antiepileptics):
1 mg intramuscularly or intravenously at birth or shortly after birth if the oral route is unsuitable.
Intramuscular and intravenous doses should not exceed 0.4 mg/kg (equivalent to 0.04 ml/kg) in premature infants weighing less than 2.5 kg (see Precautions).
The size and frequency of further doses should be based on coagulation status.
Use in elderly: Elderly patients tend to be more sensitive to reversal of anticoagulation with Inj. K MM. The dosage for this patient group should therefore be at the lower end of the ranges recommended.
Side Effects
There are isolated unconfirmed reports on the possible occurrence of anaphylactoid reactions after parenteral use of Phytomenadione mixed-micelle solutions. Very rarely, venous irritation or phlebitis has been reported in association with parenteral administration of Phytomenadione.
At the time of use, the mixed micelle ampoule solutions must be clear. Following incorrect storage, the solution may become turbid or a phase separation may occur. In such cases, the ampoule must not be used.
When patients with severely impaired liver function are treated, the formation of prothrombin may be impaired. Therefore, careful monitoring of the coagulation parameters is necessary after administration of Inj. K MM.
In potentially fatal and severe haemorrhage due to overdosage of coumarin anticoagulants, IV injections of Inj. K MM should be accompanied by a more immediately effective treatment, such as transfusions of whole blood or blood-clotting factors. When patients with prosthetic heart valves are given transfusions for the treatment of severe or potentially fatal haemorrhages, fresh frozen plasma should be used.
Large doses of Inj. K should be avoided if it is intended to continue with anticoagulant therapy.
Parenteral administration may be associated with an increased risk of kernicterus in premature infants weighing less than 2.5 kg.
Inj. K MM is contraindicated in patients with known hypersensitivity to any of its constituents.
Drug Interaction
Vitamin K1 antagonises the effect of coumarin-type anticoagulants.
Coadministration of anticonvulsants can impair the action of vitamin K1.
No overdose effects are known
Commercial Packaging
Inj K MM paediatric :Each box containing 5 ampoules of 2mg/0.2 ml.
Products from the same therapeutic group
Vitamins and Minerals
Iron, Folic Acid, B-Vitamins & Vitamin-C capsule
Alneed Gold
Iron Polymaltose Complex, Folic Acid, Zinc & Vitamin B Complex capsule
Alneed plus
Zinc, Iron, Folic Acid, B-vitamins & Vitamin-C capsule
Aritone IV
Lyophilized Vitamin-B complex & Vitamin C IV Infusion
Aritone Z
Vitamin-B Complex & Zinc Syrup
Aritone ZI
Iron, Vitamin-B Complex & Zinc Syrup
Astaxanthin 4 mg Capsule
Calcium Folinate 15 mg
Calcium tablet
Calcium & Vitamin-D
Vitamin C, D, and Folic Acid
Cavic C
Calcium & Vitamin-C effervescent tablet
Cavic C  Plus
Calcium, Vitamin-C & Vitamin-D Effervescent Tablet
Ascorbic Acid (Vitamin-C) BP
Cod Liver Oil BP
Calcitriol Injection and Capsule
Super antioxidant vitamin plus multimineral tablet
Calcium 600 + Vitamin-D 400 IU effervescent Tablet
Folic Acid BP & Zinc USP tablet
Inj. K MM
Phytomenadione BP
Inovit E
Vitamin E capsule
Calcium Orotate INN 400 mg tablet
Calcium Carbonate (Coral source) and Vitamin D3 Tablet
Levocarnitine Tablet & Solution
Osteo D
Colecalciferol injectable and oral solution
Prenatal Multivitamin & Multimineral Tablet
Preneed CI
Carbonyl Iron, Folic Acid & Zinc capsule
Proviten Gold
32 Multivitamin-Multimineral Tablet
Proviten IV
Multivitamin ( Vitamin B complex, Vitamin A,C,D and E)
Proviten JR
Multivitamins-Multiminerals Syrup
Proviten JR IV
Multivitamin Infusion
Proviten Silver
30 Multivitamin and Multimineral Tablet for Senior Citizen
Vitamin B1, B6 & B12
Vitamin A, D, B1, B2, B6, C, E, Nicotinamide and Cod liver oil Syrup
Zinc syrup